American Airlines, Goldman Sachs, Exxon Mobil Fall Premarket; Peloton, Zoom Rise
Investing.com
Published Nov 26, 2021 07:49AM ET
By Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Friday, November 26th. Please refresh for updates.
-
American Airlines (NASDAQ:AAL) stock fell over 7%, with Delta Air Lines (NYSE:DAL) and United Airlines (NASDAQ:UAL) following suit, after the emergence of a new Covid variant threatened global travel. Additionally, Carnival (NYSE:CUK) stock dropped over 10%, as did Royal Caribbean (NYSE:RCL) and Norwegian Cruise Line (NYSE:NCLH).
-
Bank of America (NYSE:BAC), Citigroup (NYSE:C), JPMorgan Chase (NYSE:JPM), Goldman Sachs (NYSE:GS), Wells Fargo (NYSE:WFC) and Morgan Stanley (NYSE:MS) all fell more than 3% on the reduced likelihood of early interest rate hikes if the Federal Reserve is worried by the new variant.
-
Exxon Mobil (NYSE:XOM) stock fell 4.4% and Chevron (NYSE:CVX) stock dropped 3.9% after crude prices slumped on concerns that the new Covid variant will lead to a fresh slowdown in global demand.
-
Zoom Video Communications (NASDAQ:ZM) stock rose 7.9% and Peloton (NASDAQ:PTON) stock climbed 5.9% as the emergence of the new Covid variant raised fears that countries could bring back restrictions on movement of people.
-
Didi (NYSE:DIDI) ADRs fell 7% after authorities in China asked the ride-hailing firm to delist from the NYSE because of security fears.
-
Tesla (NASDAQ:TSLA) stock fell 1.8% after CEO Elon Musk sold almost one million more shares of the electric car manufacturer, according to regulatory filings posted late Tuesday, bringing his sale of the company’s equity to 9.2 million and worth about $9.9 billion.
-
Pfizer (NYSE:PFE) stock climbed 6.1%, BioNTech (NASDAQ:BNTX) stock rose 7.3% and Moderna (NASDAQ:MRNA) stock surged 8.8% with investors betting that these drugmakers will get additional business for their vaccines as a result of the new Covid news.
-
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.Get The AppMerck (NYSE:MRK) stock fell 3.2% ahead of the FDA’s review of the drugmaker’s Covid-19 pill, jointly developed with Ridgeback Biotherapeutics.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.